Jeffrey Robert Ajer Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Jeffrey Robert Ajer.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Jeffrey Robert Ajer. Jeffrey Robert Ajer is Director in NEKTAR THERAPEUTICS ($NKTR) and EVP, Chief Commercial Officer in BIOMARIN PHARMACEUTICAL INC ($BMRN) and SVP, Chief Commercial Of in BIOMARIN PHARMACEUTICAL INC ($BMRN) and SVP, Chief Commercial Officer in BIOMARIN PHARMACEUTICAL INC ($BMRN).
Latest Insider Trading Transactions of Jeffrey Robert Ajer
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 09 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 78.81 | 1,537 | 121,131 | 58,250 | 59.8 K to 58.3 K (-2.57 %) |
| Apr 01 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 74.79 | 1,652 | 123,553 | 59,787 | 61.4 K to 59.8 K (-2.69 %) |
| Mar 26 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 76.30 | 1,181 | 90,110 | 61,439 | 62.6 K to 61.4 K (-1.89 %) |
| Mar 26 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 76.30 | 1,181 | 90,110 | 61,439 | 62.6 K to 61.4 K (-1.89 %) |
| Mar 23 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 78.52 | 1,513 | 118,801 | 62,620 | 64.1 K to 62.6 K (-2.36 %) |
| Mar 19 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 77.99 | 1,308 | 102,011 | 64,133 | 65.4 K to 64.1 K (-2.00 %) |
| Mar 19 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 77.99 | 1,308 | 102,011 | 64,133 | 65.4 K to 64.1 K (-2.00 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 78.39 | 26,400 | 2,069,496 | 26,400 | |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 77.21 | 1,287 | 99,369 | 65,441 | 66.7 K to 65.4 K (-1.93 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 78.39 | 5,273 | 413,350 | 66,728 | 72 K to 66.7 K (-7.32 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 10,720 | 0 | 72,001 | 61.3 K to 72 K (+17.49 %) |
| Oct 15 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 79.91 | 2,121 | 169,489 | 61,281 | 63.4 K to 61.3 K (-3.35 %) |
| Sep 30 2020 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Sell | S | 17.25 | 3,250 | 56,063 | 25,975 | 29.2 K to 26 K (-11.12 %) |
| Sep 30 2020 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Sell | S | 17.25 | 3,250 | 56,063 | 25,975 | 29.2 K to 26 K (-11.12 %) |
| Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Option Exercise | A | 18.91 | 18,200 | 344,162 | 18,200 | |
| Sep 24 2020 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Grant | A | 0.00 | 9,100 | 0 | 29,225 | 20.1 K to 29.2 K (+45.22 %) |
| Sep 21 2020 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Sell | S | 19.74 | 2,250 | 44,415 | 20,125 | 22.4 K to 20.1 K (-10.06 %) |
| Jun 23 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | M | 63.10 | 15,000 | 946,500 | 15,700 | |
| Jun 23 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 124.00 | 15,000 | 1,860,000 | 63,402 | 78.4 K to 63.4 K (-19.13 %) |
| Jun 23 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Buy | M | 63.10 | 15,000 | 946,500 | 78,402 | 63.4 K to 78.4 K (+23.66 %) |
| Jun 23 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 62.59 | 338 | 21,154 | 63,402 | 63.1 K to 63.4 K (+0.54 %) |
| Apr 09 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 79.98 | 2,407 | 192,512 | 63,064 | 65.5 K to 63.1 K (-3.68 %) |
| Apr 09 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 79.98 | 2,407 | 192,512 | 63,064 | 65.5 K to 63.1 K (-3.68 %) |
| Apr 02 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 82.00 | 1,537 | 126,034 | 65,471 | 67 K to 65.5 K (-2.29 %) |
| Mar 26 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 78.47 | 1,618 | 126,964 | 67,008 | 68.6 K to 67 K (-2.36 %) |
| Mar 26 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 74.36 | 2,041 | 151,769 | 68,626 | 70.7 K to 68.6 K (-2.89 %) |
| Mar 24 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 73.05 | 3,599 | 262,907 | 70,667 | 74.3 K to 70.7 K (-4.85 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 73.82 | 29,590 | 2,184,334 | 29,590 | |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 10,380 | 0 | 74,266 | 63.9 K to 74.3 K (+16.25 %) |
| Mar 17 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 84.50 | 7,644 | 645,918 | 63,886 | 71.5 K to 63.9 K (-10.69 %) |
| Mar 04 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 9,586 | 0 | 71,530 | 61.9 K to 71.5 K (+15.48 %) |
| Oct 01 2019 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Sell | S | 18.06 | 2,375 | 42,893 | 22,375 | 24.8 K to 22.4 K (-9.60 %) |
| Sep 27 2019 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Option Exercise | A | 18.80 | 13,000 | 244,400 | 13,000 | |
| Sep 27 2019 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Grant | A | 0.00 | 6,500 | 0 | 24,750 | 18.3 K to 24.8 K (+35.62 %) |
| Sep 24 2019 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Sell | S | 20.24 | 2,250 | 45,540 | 18,250 | 20.5 K to 18.3 K (-10.98 %) |
| Jun 07 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 68.78 | 309 | 21,254 | 61,994 | 61.7 K to 62 K (+0.50 %) |
| Jun 06 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 14,160 | 0 | 61,635 | 47.5 K to 61.6 K (+29.83 %) |
| Mar 27 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 89.18 | 3,656 | 326,025 | 47,475 | 51.1 K to 47.5 K (-7.15 %) |
| Mar 26 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 88.05 | 3,598 | 316,804 | 51,131 | 54.7 K to 51.1 K (-6.57 %) |
| Mar 25 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 90.47 | 1,930 | 174,614 | 54,729 | 56.7 K to 54.7 K (-3.41 %) |
| Mar 25 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 89.62 | 2,589 | 232,020 | 56,659 | 59.2 K to 56.7 K (-4.37 %) |
| Mar 21 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 93.07 | 3,728 | 346,965 | 59,248 | 63 K to 59.2 K (-5.92 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 94.53 | 23,450 | 2,216,729 | 23,450 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 9,370 | 0 | 62,976 | 53.6 K to 63 K (+17.48 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 94.53 | 7,169 | 677,686 | 53,606 | 60.8 K to 53.6 K (-11.80 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 94.76 | 917 | 86,895 | 60,775 | 61.7 K to 60.8 K (-1.49 %) |
| Mar 05 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,557 | 0 | 61,692 | 49.1 K to 61.7 K (+25.56 %) |
| Nov 16 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | M | 63.10 | 9,000 | 567,900 | 30,700 | |
| Nov 16 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 94.35 | 600 | 56,611 | 49,135 | 49.7 K to 49.1 K (-1.21 %) |
| Nov 16 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 93.81 | 799 | 74,957 | 49,735 | 50.5 K to 49.7 K (-1.58 %) |
| Nov 16 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 92.21 | 2,400 | 221,297 | 50,534 | 52.9 K to 50.5 K (-4.53 %) |
| Nov 16 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 91.62 | 5,201 | 476,494 | 52,934 | 58.1 K to 52.9 K (-8.95 %) |
| Nov 16 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Buy | M | 63.10 | 9,000 | 567,900 | 58,135 | 49.1 K to 58.1 K (+18.32 %) |
| Oct 05 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 98.98 | 1,000 | 98,985 | 49,135 | 50.1 K to 49.1 K (-1.99 %) |
| Oct 01 2018 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Option Exercise | A | 60.91 | 9,500 | 578,645 | 9,500 | |
| Oct 01 2018 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Grant | A | 0.00 | 4,750 | 0 | 20,500 | 15.8 K to 20.5 K (+30.16 %) |
| Sep 21 2018 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Sell | S | 56.76 | 6,750 | 383,130 | 15,750 | 22.5 K to 15.8 K (-30.00 %) |
| Jun 13 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 90.31 | 1,436 | 129,685 | 50,135 | 51.6 K to 50.1 K (-2.78 %) |
| Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 92.07 | 1,414 | 130,187 | 51,571 | 53 K to 51.6 K (-2.67 %) |
| May 09 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 85.96 | 309 | 26,562 | 52,914 | 53.2 K to 52.9 K (-0.58 %) |
| May 09 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 68.78 | 309 | 21,254 | 53,223 | 52.9 K to 53.2 K (+0.58 %) |
| Apr 03 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 80.12 | 2,119 | 169,774 | 52,914 | 55 K to 52.9 K (-3.85 %) |
| Mar 30 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 79.69 | 1,537 | 122,484 | 55,033 | 56.6 K to 55 K (-2.72 %) |
| Mar 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 81.36 | 3,583 | 291,513 | 56,570 | 60.2 K to 56.6 K (-5.96 %) |
| Mar 23 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 83.90 | 4,368 | 366,475 | 60,153 | 64.5 K to 60.2 K (-6.77 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 83.57 | 41,040 | 3,429,713 | 41,040 | |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,840 | 0 | 64,521 | 51.7 K to 64.5 K (+24.84 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 83.57 | 3,651 | 305,114 | 51,681 | 55.3 K to 51.7 K (-6.60 %) |
| Mar 13 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 82.39 | 2,972 | 244,863 | 55,332 | 58.3 K to 55.3 K (-5.10 %) |
| Mar 06 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 79.86 | 1,614 | 128,894 | 58,304 | 59.9 K to 58.3 K (-2.69 %) |
| Feb 28 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,529 | 0 | 59,918 | 47.4 K to 59.9 K (+26.44 %) |
| Sep 26 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | M | 37.46 | 2,166 | 81,138 | 0 | |
| Sep 26 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | M | 37.46 | 1,355 | 50,758 | 2,166 | |
| Sep 26 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 95.00 | 2,166 | 205,770 | 47,944 | 50.1 K to 47.9 K (-4.32 %) |
| Sep 26 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Buy | M | 37.46 | 2,166 | 81,138 | 50,110 | 47.9 K to 50.1 K (+4.52 %) |
| Sep 26 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 95.00 | 1,355 | 128,725 | 47,944 | 49.3 K to 47.9 K (-2.75 %) |
| Sep 26 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Buy | M | 37.46 | 1,355 | 50,758 | 49,299 | 47.9 K to 49.3 K (+2.83 %) |
| Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Option Exercise | A | 21.75 | 22,500 | 489,375 | 22,500 | |
| Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Option Exercise | A | 21.75 | 33,750 | 734,063 | 33,750 | |
| Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Grant | A | 0.00 | 9,000 | 0 | 22,500 | 13.5 K to 22.5 K (+66.67 %) |
| Sep 21 2017 | NKTR | NEKTAR THERAPEUTIC ... | Ajer Jeffrey Robert | Director | Grant | A | 0.00 | 13,500 | 0 | 13,500 | 0 to 13.5 K |
| Jun 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 89.61 | 1,004 | 89,968 | 47,944 | 48.9 K to 47.9 K (-2.05 %) |
| Jun 06 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 90.72 | 1,488 | 134,991 | 48,948 | 50.4 K to 48.9 K (-2.95 %) |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 91.50 | 1,096 | 100,284 | 50,436 | 51.5 K to 50.4 K (-2.13 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | M | 38.59 | 3,498 | 134,988 | 0 | |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | M | 28.23 | 988 | 27,891 | 0 | |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 99.00 | 3,498 | 346,302 | 51,532 | 55 K to 51.5 K (-6.36 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Buy | M | 38.59 | 3,498 | 134,988 | 55,030 | 51.5 K to 55 K (+6.79 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 99.00 | 988 | 97,812 | 51,532 | 52.5 K to 51.5 K (-1.88 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Buy | M | 28.23 | 988 | 27,891 | 52,520 | 51.5 K to 52.5 K (+1.92 %) |
| May 04 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 96.74 | 302 | 29,215 | 51,532 | 51.8 K to 51.5 K (-0.58 %) |
| May 04 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 70.30 | 302 | 21,232 | 51,834 | 51.5 K to 51.8 K (+0.59 %) |
| Mar 31 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 89.15 | 3,890 | 346,794 | 51,532 | 55.4 K to 51.5 K (-7.02 %) |
| Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 87.42 | 39,480 | 3,451,342 | 39,480 | |
| Mar 24 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,200 | 0 | 55,422 | 43.2 K to 55.4 K (+28.23 %) |
| Mar 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 92.50 | 3,288 | 304,140 | 43,222 | 46.5 K to 43.2 K (-7.07 %) |
| Mar 08 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 90.56 | 5,000 | 452,800 | 46,510 | 51.5 K to 46.5 K (-9.71 %) |
| Mar 07 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 93.95 | 1,749 | 164,319 | 51,510 | 53.3 K to 51.5 K (-3.28 %) |
| Sep 29 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 95.61 | 18,467 | 1,765,648 | 41,342 | 59.8 K to 41.3 K (-30.88 %) |
| Jun 07 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 90.00 | 1,488 | 133,920 | 59,809 | 61.3 K to 59.8 K (-2.43 %) |
| May 17 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 82.71 | 1,096 | 90,650 | 61,297 | 62.4 K to 61.3 K (-1.76 %) |
| May 12 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 80.80 | 679 | 54,863 | 62,393 | 63.1 K to 62.4 K (-1.08 %) |
| May 04 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 86.03 | 415 | 35,701 | 63,072 | 63.5 K to 63.1 K (-0.65 %) |
| May 04 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 51.26 | 415 | 21,275 | 63,487 | 63.1 K to 63.5 K (+0.66 %) |
| Mar 17 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 83.43 | 36,280 | 3,026,840 | 36,280 | |
| Mar 17 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 16,190 | 0 | 63,072 | 46.9 K to 63.1 K (+34.53 %) |
| Mar 07 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Sell | S | 88.42 | 1,255 | 110,970 | 46,882 | 48.1 K to 46.9 K (-2.61 %) |
| Mar 07 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Payment of Exercise | F | 89.57 | 2,395 | 214,520 | 48,137 | 50.5 K to 48.1 K (-4.74 %) |
| Mar 02 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Payment of Exercise | F | 81.87 | 17,656 | 1,445,497 | 50,532 | 68.2 K to 50.5 K (-25.89 %) |
| Feb 26 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Grant | A | 0.00 | 5,883 | 0 | 68,188 | 62.3 K to 68.2 K (+9.44 %) |
| Feb 26 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Grant | A | 0.00 | 19,840 | 0 | 62,305 | 42.5 K to 62.3 K (+46.72 %) |
| Feb 26 2016 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Grant | A | 0.00 | 6,860 | 0 | 42,465 | 35.6 K to 42.5 K (+19.27 %) |
| Nov 06 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Sell | S | 117.56 | 26 | 3,057 | 35,605 | 35.6 K to 35.6 K (-0.07 %) |
| Nov 06 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Grant | A | 57.26 | 26 | 1,489 | 35,631 | 35.6 K to 35.6 K (+0.07 %) |
| Jul 22 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Option Exercise | M | 63.10 | 3,000 | 189,300 | 39,700 | |
| Jul 22 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Sell | S | 150.00 | 3,000 | 450,000 | 35,605 | 38.6 K to 35.6 K (-7.77 %) |
| Jul 22 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Buy | M | 63.10 | 3,000 | 189,300 | 38,605 | 35.6 K to 38.6 K (+8.43 %) |
| Jun 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Sell | S | 122.35 | 1,362 | 166,646 | 35,605 | 37 K to 35.6 K (-3.68 %) |
| Jun 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Payment of Exercise | F | 120.46 | 1,488 | 179,244 | 36,967 | 38.5 K to 37 K (-3.87 %) |
| Jun 03 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Sell | S | 123.76 | 377 | 46,657 | 38,455 | 38.8 K to 38.5 K (-0.97 %) |
| Jun 03 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Payment of Exercise | F | 125.57 | 413 | 51,860 | 38,832 | 39.2 K to 38.8 K (-1.05 %) |
| May 26 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Sell | S | 126.55 | 1,625 | 205,647 | 39,245 | 40.9 K to 39.2 K (-3.98 %) |
| May 19 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Payment of Exercise | F | 122.78 | 1,096 | 134,567 | 40,870 | 42 K to 40.9 K (-2.61 %) |
| May 12 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Payment of Exercise | F | 121.66 | 679 | 82,607 | 41,966 | 42.6 K to 42 K (-1.59 %) |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Option Exercise | M | 37.46 | 8,671 | 324,816 | 2,166 | |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Option Exercise | M | 37.46 | 808 | 30,268 | 1,355 | |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Option Exercise | M | 28.23 | 5,258 | 148,433 | 0 | |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Option Exercise | M | 28.23 | 2,642 | 74,584 | 978 | |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Option Exercise | M | 21.51 | 3,125 | 67,219 | 0 | |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Option Exercise | M | 21.51 | 625 | 13,444 | 0 | |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Option Exercise | M | 38.59 | 12,502 | 482,452 | 0 | |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Sell | S | 119.20 | 388 | 46,248 | 42,645 | 43 K to 42.6 K (-0.90 %) |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Sell | S | 119.14 | 33,631 | 4,006,794 | 43,033 | 76.7 K to 43 K (-43.87 %) |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Buy | M | 37.46 | 8,671 | 324,816 | 76,664 | 68 K to 76.7 K (+12.75 %) |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Buy | M | 37.46 | 808 | 30,268 | 67,993 | 67.2 K to 68 K (+1.20 %) |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Buy | M | 28.23 | 5,258 | 148,433 | 67,185 | 61.9 K to 67.2 K (+8.49 %) |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Buy | M | 28.23 | 2,642 | 74,584 | 61,927 | 59.3 K to 61.9 K (+4.46 %) |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Buy | M | 21.51 | 3,125 | 67,219 | 59,285 | 56.2 K to 59.3 K (+5.56 %) |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Buy | M | 21.51 | 625 | 13,444 | 56,160 | 55.5 K to 56.2 K (+1.13 %) |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Buy | M | 38.59 | 12,502 | 482,452 | 55,535 | 43 K to 55.5 K (+29.05 %) |
| May 08 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Grant | A | 51.26 | 943 | 48,341 | 43,033 | 42.1 K to 43 K (+2.24 %) |
| Mar 05 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Option Exercise | A | 108.36 | 23,900 | 2,589,804 | 23,900 | |
| Mar 05 2015 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Grant | A | 0.00 | 10,500 | 0 | 42,090 | 31.6 K to 42.1 K (+33.24 %) |
| Dec 05 2014 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Option Exercise | M | 38.59 | 12,000 | 463,080 | 12,502 | |
| Dec 05 2014 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Sell | S | 91.01 | 12,000 | 1,092,161 | 31,590 | 43.6 K to 31.6 K (-27.53 %) |
| Dec 05 2014 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Buy | M | 38.59 | 12,000 | 463,080 | 43,590 | 31.6 K to 43.6 K (+37.99 %) |
| Nov 05 2014 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Sell | S | 83.54 | 47 | 3,926 | 31,590 | 31.6 K to 31.6 K (-0.15 %) |
| Nov 05 2014 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Grant | A | 31.26 | 47 | 1,469 | 31,637 | 31.6 K to 31.6 K (+0.15 %) |
| Jun 06 2014 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Option Exercise | A | 63.10 | 42,700 | 2,694,370 | 42,700 | |
| Jun 06 2014 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | SVP, Chief Commerci ... | Grant | A | 0.00 | 11,400 | 0 | 31,590 | 20.2 K to 31.6 K (+56.46 %) |